Tumors induce coordinate growth of artery, vein, and lymphatic vessel triads by Alanna Ruddell et al.
Ruddell et al. BMC Cancer 2014, 14:354
http://www.biomedcentral.com/1471-2407/14/354RESEARCH ARTICLE Open AccessTumors induce coordinate growth of artery, vein,
and lymphatic vessel triads
Alanna Ruddell1,2*, Alexandra Croft2, Karen Kelly-Spratt1, Momoko Furuya1 and Christopher J Kemp1,3Abstract
Background: Tumors drive blood vessel growth to obtain oxygen and nutrients to support tumor expansion, and
they also can induce lymphatic vessel growth to facilitate fluid drainage and metastasis. These processes have
generally been studied separately, so that it is not known how peritumoral blood and lymphatic vessels grow
relative to each other.
Methods: The murine B16-F10 melanoma and chemically-induced squamous cell carcinoma models were employed
to analyze large red-colored vessels growing between flank tumors and draining lymph nodes. Immunostaining and
microscopy in combination with dye injection studies were used to characterize these vessels.
Results: Each peritumoral red-colored vessel was found to consist of a triad of collecting lymphatic vessel, vein,
and artery, that were all enlarged. Peritumoral veins and arteries were both functional, as detected by intravenous
dye injection. The enlarged lymphatic vessels were functional in most mice by subcutaneous dye injection assay,
however tumor growth sometimes blocked lymph drainage to regional lymph nodes. Large red-colored vessels
also grew between benign papillomas or invasive squamous cell carcinomas and regional lymph nodes in chemical
carcinogen-treated mice. Immunostaining of the red-colored vessels again identified the clustered growth of enlarged
collecting lymphatics, veins, and arteries in the vicinity of these spontaneously arising tumors.
Conclusions: Implanted and spontaneously arising tumors induce coordinate growth of blood and lymphatic vessel
triads. Many of these vessel triads are enlarged over several cm distance between the tumor and regional lymph nodes.
Lymphatic drainage was sometimes blocked in mice before lymph node metastasis was detected, suggesting that an
unknown mechanism alters lymph drainage patterns before tumors reach draining lymph nodes.
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Blood and lymphatic vessels arise during embryogenesis
and mature by an orderly program of gene expression, sig-
naling, and morphogenesis that establishes a triad ar-
rangement of lymphatic, vein, and artery throughout the
body [1,2]. The formation of each vessel type is regulated
by different combinations of transcription factors (e.g.
Notch, COUP-TFII, and Prox1), While some factors spe-
cifically regulate lymphatic (Prox1), vein (COUP-TFII), or
artery formation (Hey1/2), other vascular signaling path-
ways show overlapping activities (e.g. Sox transcription
factors, and vascular endothelial growth factors (VEGFs)* Correspondence: ruddella@uw.edu
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unless otherwise stated.[3-5]. Intercellular signaling of proteins including sema-
phorins, ephrins, and chemokines helps to pattern forma-
tion of the network of lymphatic and blood vessels, while
VEGF family members are important to support growth
of the lymphatic and blood vasculature. Mature triads of
lymphatics, arteries, and veins are maintained in the adult
unless activated by events requiring vascularization such as
tumorigenesis [6].
Tumors induce extensive growth of blood vessels to
obtain oxygen and nutrients essential for their continued
expansion and progression [7,8]. The resulting blood
vessels are variable and abnormal, ranging in size and
morphology from capillaries and small blood vessels to
larger feeder arteries and draining veins surrounding the
tumor vascular bed [9]. The lymphatic vasculature can
also expand [10-12], to increase lymph drainage froml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Ruddell et al. BMC Cancer 2014, 14:354 Page 2 of 11
http://www.biomedcentral.com/1471-2407/14/354tumors featuring high interstitial fluid pressure [13,14], and
also to promote metastasis of tumors to draining lymph
nodes (LNs) [15,16]. Tumors can produce growth factors
promoting angiogenesis (eg. VEGF-A, placental growth
factor), as well as lymphangiogenesis (VEGF-C, −D), al-
though the resulting vessels are highly abnormal relative to
those of embryos [17,18], presumably due to aberrant sig-
naling [9,19]. These vessels can actively increase blood cir-
culation and lymph drainage, or they can become so
abnormal that they are unable to transport blood [20] or
lymph [14,21].
Tumor-induced angiogenesis and lymphangiogenesis
are generally studied separately, raising the question of
whether the normal triad pattern of lymphatic, vein, and
artery is used to support tumor vessel growth, or if
blood and lymphatic vessels are independently generated
and patterned during tumor growth. In this study we
utilized two murine models to compare the growth of
large peritumoral lymphatic and blood vessels. The syn-
geneic B16-F10 melanoma model [22] permits ready
visualization of peritumoral vasculature on the flank skin
of C57Bl/6 mice, and these tumors metastasize via the
lymphatics to draining lymph nodes (LNs) [23-25]. The
second model used was an autochthonous squamous cell
carcinoma induced by DMBA mutagenesis, followed by
repeated TPA promoter treatments of outbred mice
[26]. These naturally arising tumors first present as exo-
phytic benign papillomas, which can convert to endo-
phytic invasive carcinomas capable of metastasizing to
draining LNs or to the lung. Both of these tumor models
induced growth of large red-colored blood vessels in the
skin extending several cm between the primary tumor
and regional draining LNs. Immunohistochemical and
functional analysis determined that these enlarged ves-
sels included large arteries, veins, and one or more lym-
phatics, indicating that tumor-induced vessel growth




Mice were maintained in micro-isolator rooms under
specific pathogen-free conditions. Experiments involving
animals were approved by the FHCRC Animal Care and
Use Committee. For the B16-F10 tumor model, four
week-old C57Bl/6 mice were purchased from Jackson
Laboratories (Bar Harbor, ME). B16-F10 murine melan-
oma cells [27] from the American Type Culture Collection
(Manassas, VA) were tested to confirm that the cells were
free of mycoplasma contamination (Cambrex, Rockland,
MD). Mice were anesthetized with isoflurane and subcuta-
neously injected in the left flank with 15,000 B16-F10 cells
in 50 μl of Hanks’ buffered saline solution, while the con-
trol right flanks were injected with 50 μl of Hanks’ bufferedsaline solution [24,25]. Mice were euthanized after 14–23
days, when tumors were 1–2 cm in diameter. Vessel diam-
eter was measured using a ruler. Using a scalpel, single
large red-colored blood vessels in the flank skin were
dissected in 2 mm × 5 sections. Tissue was fixed in
4% paraformaldehyde at room temp for 4 h, incubated
in 30% sucrose/PBS overnight at 4°C, and mounted in
Tissue-Tek O.C.T. compound (Sakura; Torrance, CA) be-
fore cryosectioning at −25°C.
For the DMBA/TPA squamous cell carcinoma model,
wild-type NIH/Ola or p19Arf+/− mice were treated on
the shaved dorsal skin with DMBA, and then twice
weekly with TPA for 15 weeks to induce papillomas and
squamous cell carcinomas, as previously described [28,29].
Mice were euthanized 28 to 32 weeks after DMBA treat-
ment, or if moribund. More than a dozen papillomas or
carcinomas arose on the back skin of each mouse, with di-
ameters ranging from 2 to 15 mm. Large vessels draining
papillomas or carcinomas were dissected from the interior
surface of the skin in 2 mm × 5 mm sections with a scalpel,
and mounted in O.C.T. for cryosectioning.
Functional labeling of lymphatic and blood vessels
Functional lymphatic vessels were identified by lymphog-
raphy, injecting isoflurane-anesthetized mice subcutane-
ously in the base of the tail with 0.25% lysine-fixable
Texas Red Dextran (Invitrogen; Gran Island, NY) and
2.5% Evans Blue (Sigma; St. Louis, MO) in 100 μl Hanks’
buffered saline solution, followed 20 min later by CO2
overdose and necropsy. The blood circulation was labeled
by injecting mice intravenously in the tail vein with
0.05% Fluorescein isothiocyanate (FITC) – Lycopersicon
esculentum lectin (Vector Laboratories; Burlingame, CA)
in 100 μl Hank’s buffered saline solution in the tail vein,
immediately followed by CO2 overdose, followed by dis-
section of vessels. Vessels were mounted in OCT for
cryosectioning.
Immunostaining analysis and vessel quantitation
Twelve μm cryosections were fixed in 4% paraformal-
dehyde for 10 min, followed by incubation in 0.3%
hydrogen peroxide in methanol for 30 min. Sections
were then immunostained with CD31 (BD Pharmingen),
MECA −32 (BD Pharmingen), LYVE-1 (Ebioscience), or
10.1.1 [30], as previously described [24]. Immunohis-
tochemical staining was detected using horseradish
peroxidase-labeled secondary antibodies and Vector VIP
detection, followed by brief methyl green counterstaining
at room temperature (Vector Laboratories). In some ex-
periments, sections were immunostained with 10.1.1 and
Prox1 (Millipore; Billerica, MD), and detected with Alexa
568-anti-hamster and Alexa 488-conjugated anti-rabbit
antibodies (Invitrogen; Sparks, MD), respectively, followed
by mounting in Prolong Gold (Invitrogen).
Figure 1 Growth of peritumoral lymphatic and blood vessels in
a melanoma model. a). Schematic of B16-F10 melanoma flank
tumor, associated SE, IF, and ODD vessels, and regional LNs. The
boxes around vessels illustrate regions dissected for microscopic
analysis. b). Necropsy of melanoma-bearing mouse identifies greatly
enlarged red-colored peritumoral vessels. The tumor-draining AX
LNs are outlined by dotted white circles, while dotted black circles
outline the ING LNs. The arrows point to the SE vessels, while the
black arrowheads identify the IF vessels. The dotted black boxes
show the flank regions analyzed at higher magnification in (c) and
(d). c) Arrow points to Evans Blue-filled SE lymphatic vessel adjacent
to red-colored SE blood vessel on normal flank. d). Arrow points to
enlarged Evans Blue-filled SE lymphatic vessel draining tumor and
ING LN, next to enlarged red-colored blood vessels. The white
arrowhead identifies an ODD vessel not seen in the normal flank
skin. Scale bar 1 mm.
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atic, vein, and artery size, three sections from each vessel
were viewed at 100x magnification, and vessels were out-
lined to measure the area using the NIS Elements BR
3.0 program (Nikon, Inc.; Melville, NY). Area measure-
ments were analyzed for significance by Mann–Whitney
U two-tailed test.
Results
Peritumoral blood and lymphatic vessels are enlarged
Prominent red-colored blood vessels surround B16-F10
melanoma tumors implanted in the flank of syngeneic
C57Bl/6 wild-type mice (Figure 1a), often growing toward
regional draining LNs. These enlarged vessels (Figure 1b)
often reach several millimeters in diameter (Figure 1d) as
compared to the normal small vessels of the contralateral
non-tumor-draining flank (Figure 1c). The affected vascu-
lature in the flank region included the major superficial
epigastric blood vessel (SE) connecting the inguinal (ING)
and axillary (AX) LNs along the milk line, and the ingui-
nofemoral (IF) vessel connecting the inguinal LN with
central vessels (Figure 1a). Other abnormal red-colored
vessels (ODD) variably appeared in adjacent regions of the
flank skin (e.g. arrowhead, Figure 1d) in regions that nor-
mally do not contain large blood vessels (Figure 1c). These
phenotypes of increased SE, IF, and ODD vessel growth
were identified in all twelve of the tumor-bearing mice an-
alyzed in this study.
We tested whether this angiogenesis also involves
lymphatic vessels, as the SE blood vessel between the
ING and AX LNs tracks with a major lymphatic vessel
draining from the ING LN [31]. A functional assay was
used to identify lymphatic vessels associated with the
tumor blood vessels, by injecting Evans Blue dye sub-
cutaneously into the base of the tail to label the ING
and AX LN lymphatic drainage on both flanks [32]. This
injection identified the blue collecting lymphatic vessel
adjacent to the SE blood vessel (Figure 1b). The labeled
SE lymphatic vessel was much larger on the tumor-
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control flank (Figure 1c). These tumors therefore in-
duced enlargement of the SE lymphatic vessel adjacent
to the SE blood vessels. The ING and AX LNs on each
side also labeled with Evans Blue (Figure 1b), indicating
that this lymphatic drainage is not blocked by tumor
growth. The second-tier AX LN preferentially filled with
Evans Blue dye on the tumor-draining side relative to
the control side (Figure 1b), consistent with our previous
reports that B16-F10 tumors accelerate lymph drainage
[24,33].
Identification of functional lymphatic and blood vessels
The composition of the SE vessels was investigated by
immunostaining with antibodies to lymphatic and blood
endothelial surface markers. Fixation of the dissected
vessel in paraformaldehyde followed by 30% sucrose
impregnation was used to preserve the red blood cells
within blood vessels to confirm their identify. This fix-
ation technique also helped to keep the vessels patent to
facilitate comparison of their size. First, a normal SE ves-
sel was dissected, cryosectioned, and immunostained.
The CD31 antibody recognizes PECAM expressed on
lymphatics, veins, and arteries [34]. CD31 immunostain-
ing revealed that the single SE “vessel” consisted of
a grouped lymphatic, vein, and artery in normal mice
(Figure 2a). The 10.1.1 antibody recognizes mCLCA1Figure 2 Triad arrangement of normal SE lymphatic, vein, and artery.
(V) and artery (a), with Methyl Green nuclear counterstaining. b). 10.1.1 imm
nonspecific staining in the upper right corner is myoglobin pseudoperoxid
labels the artery and vein, demonstrating that they are functional in circula
base labels the lymphatic vessel, indicating that it is functional in circulatin[35], which is expressed on the surface of lymphatic but
not blood endothelium [36]. 10.1.1 antibody immuno-
staining identified the collecting lymphatic vessel but
not the SE blood vessels (Figure 2b). The SE lymphatic
vessel was negative for LYVE-1 (data not shown), con-
sistent with previous reports that collecting lymphatics
do not express LYVE-1 [37]. The vascular endothelial
marker antibody MECA-32 variably immunostained
these vessels under the fixation conditions used (data
not shown), and is reported to be variably expressed in
tumor blood vessels [38]. The 10.1.1 and CD31 anti-
bodies were therefore selected as the best combination
to distinguish lymphatic and blood vessels by immuno-
staining. The vessels are further distinguished from each
other by their anatomical characteristics, as arteries are
rounded with a narrow lumen and thick wall, while veins
and lymphatics are thin-walled with a larger irregularly
shaped lumen.
Dye injection assays were used to functionally distin-
guish these vessels. Intravenous injection of FITC lyso-
persicon esculentum lectin [20] labeled the vascular
endothelium and erythrocytes of the SE artery and vein,
but not the lymphatic vessel of normal control mice
(Figure 2c). Subcutaneous injection of lysine-fixable
Texas Red Dextran (15 kd MW) into the lateral tail base
[32] preferentially labeled the draining lymphatic vessel
(Figure 2d). These functional immunostaining assaysa). CD31 immunohistochemical purple staining of lymphatic (L) vein
unohistochemical staining identifies the SE lymphatic vessel. The
ase-positive muscle. c). Intravenously injected FITC L. lycopersicum lectin
ting blood. d). Texas Red Dextran injected subcutaneously into the tail
g lymph. Scale bar 50 μm.
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bels CD31-positive blood vessels, while subcutaneously-
delivered Texas Red Dextran identifies 10.1.1-positive
lymphatic vessels.
Peritumoral growth of lymphatic, artery, and vein triads
The enlarged SE vessels draining B16-F10 tumors were
characterized by cryosectioning and immunostaining with
the 10.1.1 and CD31 antibodies, and by comparison with
the morphology of normal contralateral SE vessels, which
consist of an artery, vein, and one or more lymphatic
vessels. CD31 immunostaining identified a large tumor-
draining vein, artery, and lymphatic vessel (Figure 3a),
while 10.1.1 immunostaining identified only the lymphatic
vessel (Figure 3b). These peritumoral blood and lymphatic
vessels are much larger than the corresponding normal
contralateral vessels (Figure 2), in agreement with the
grossly visible enlargement of the red-colored blood ves-
sels and Evans Blue dye-positive lymphatic vessels of
tumor-bearing mice (Figure 1b). This enlargement of SE
lymphatic and blood vessels was a consistent feature of
B16-F10 tumors growing on the flank. This growth effect
spread over distances up to several centimeters away from
the tumor, as enlargement of the SE lymphatic and blood
vessels extends all the way to the AX LN (Figure 1b).Figure 3 Enlarged and functional peritumoral SE lymphatic, vein, and
enlarged and abnormal triad of peritumoral SE lymphatic, vein, and artery.
identifies the SE lymphatic vessel. c). Subcutaneously injected Texas Red De
into the SE vein and artery after 20 min. d). Red 10.1.1 immunofluorescent
in (c), and an additional collapsed lymphatic vessel. e). Green nuclear Prox1
lymphatic vessels. f). Merging of the 10.1.1 (d) and Prox1 images (e) confir
bars 50 μm.Dye was injected subcutaneously into the tail to
test whether the enlarged tumor-draining lymphatic ves-
sels are able to transport fluid, as tumor-draining lym-
phatics can be compressed and nonfunctional [21].
Injected Texas Red Dextran labeled the 10.1.1 Ab-
positive lymphatic vessel, indicating that it is functional in
draining lymph from the tail past the tumor and through
the ING LN to travel through the efferent SE lymphatic
vessels (Figure 3c). In addition, the artery and vein were
labeled with Texas Red Dextran (Figure 3c), indicating
that the dye traveled from the lymphatic drainage to the
heart and into the blood circulation 20 minutes after in-
jection. [33]. This is consistent with our previous reports
that dye reaches the vascular circulation within minutes in
mice with cancer, due to increased lymph flow [33,36].
The circulation of subcutaneously injected lectin in
lymphatic as well as blood vessels reveals that both types
of vessels are functional.
Prox1 immunostaining was used to confirm the lymph-
atic identity of the abnormally enlarged 10.1.1 Ab-positive
SE lymphatic vessel, as Prox1 is a transcription factor
expressed in lymphatic but not vascular endothelium [39].
The endothelial cells of the SE lymphatic vessel of
Figure 3c and adjacent lymphatic vessels co-expressed sur-
face 10.1.1 (Figure 3d) and nuclear Prox1 (Figure 3e, f ),artery triad. a). CD31 immunohistochemical staining identifies
b). 10.1.1 immunohistochemical staining of the same vessel triad
xtran circulates through the peritumoral SE lymphatic vessel and then
staining of an adjacent section identifies the lymphatic vessel shown
immunofluorescent staining identifies the endothelium of both
ms that the 10.1.1-positive lymphatic vessels express Prox1. Scale
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These findings identify the 10.1.1 antibody as a marker
of collecting lymphatic vessels, in addition to its previ-
ously described utility for identification of initial lymphatic
vessels [36].
The visible enlargement of SE and IF lymphatic and blood
vessels was consistently observed in the 12 melanoma-
bearing mice used for these studies. The growth of the
SE lymphatic, vein, and artery was compared by esti-
mating the area of each vessel from immunostaining
images. The estimated area of the tumor-draining lym-
phatics, veins and arteries increased 12-, 9-, and 6-fold
relative to uninvolved contralateral SE vessels, respectively
(Figure 4), and these increases were all statistically signifi-
cant by t test (p < 0.0001). These increases are likely un-
derestimates, as the vessels were often collapsed after
dissection (eg. lymphatic vessel in Figure 3b). Nonetheless,
these comparisons confirm the visual observations that
B16-F10 melanomas consistently induce growth of en-
larged triads including lymphatics, veins, and artery.
Coordinate growth of peritumoral lymphatic and blood
vessels
B16-F10 tumor growth in the flank was associated
with other enlarged vessels in addition to the SE vessels
(Figure 1b), which could potentially also involve clus-
tered growth of lymphatic, vein, and artery. The inguino-
femoral (IF) blood vessel connecting the ING LN with
the midline was consistently enlarged in the area of
the tumor and where it travels dorsal to the ING LN
to join the SE vessels (black arrowhead, Figure 1b). Vari-
able “new” vessels were also seen near the tumor, and
also appearing at some distance branching from the SE
or IF vessels (e.g. white arrowhead, Figure 1d). TheseFigure 4 Coordinate growth of lymphatics, veins, and arteries
in triads. Area of tumor-draining and contralateral control SE
lymphatics, veins, and arteries were estimated by quantitation of
immunostained images. Data is averaged from 18 measurements of
vessel triads from 6 mice. The tumor-draining lymphatics, veins and
arteries are all significantly enlarged (Mann Whitney U two-tailed
test, ***, p < 0.0001).vessels were dissected, cryosectioned, and analyzed by
immunostaining. CD31 immunostaining of the contra-
lateral non-tumor-draining IF vessels identified a normal
small lymphatic, vein, and artery close to each other
(Figure 5a), while 10.1.1 Ab immunostaining was re-
stricted to the lymphatic vessel (Figure 5b). Subcutane-
ous Texas Red Dextran injection identified all three of
the vessels (Figure 5c), confirming that that these vessels
are all functional, and that increased lymphatic drainage
in this tumor-bearing mouse rapidly delivers lymph into
the blood circulation.
The IF vessel dissected from the tumor-bearing flank
also included a lymphatic, vein, and artery (Figure 5d, e),
that were all enlarged relative to the contralateral control
vessels (Figure 5a, b). Subcutaneously delivered Texas
Red Dextran identified the vein and artery but not the
lymphatic vessel (Figure 5f). Tumor growth in this par-
ticular mouse therefore blocked IF lymphatic drainage,
while other tail-draining lymphatic vessels instead deliv-
ered Texas Red Dextran to the blood circulation.
The ODD vessels also consisted of triads of enlarged
lymphatics, veins, and arteries by immunostaining for
CD31 (Figure 5g) and 10.1.1 (Figure 5h). In the example
shown, the lymphatic and blood vessels were all func-
tional, as subcutaneously injected Texas Red Dextran la-
beled lymphatic as well as blood vessels (Figure 5i).
There are no vessels visible in comparable regions of the
contralateral control flank (Figure 1c) so that it remains
to be determined whether these ODD vessels are derived
by expansion of pre-existing very small vessel triads, or
by some other mechanism.
Pre-metastatic tumors sometimes block lymph drainage
Lymph drainage was occasionally impaired by growth of
B16-F10 tumors, as detected by failure of subcutaneously
injected Texas Red Dextran to appear in the tumor-
draining lymphatic vessel, while it reached the circulation
via other lymphatics to be detected in the blood vessels
(e.g. Figure 5f). This phenotype was further investigated
by examining the visible drainage of Evans Blue Dye into
the ING and AX LNs. Subcutaneous Evans Blue injection
into the tail generally labeled both the ING and AX LNs
(dotted circles, Figure 1b) in 8 of 12 tumor-bearing mice
injected with dye. However, 4 of the 12 mice showed
blocked drainage on the tumor-draining side, with blue
dye draining to the ING LN (Figure 6e) but not continu-
ing to the AX LN on the tumor-draining side (Figure 6c),
while dye drainage through the control contralateral ING
(Figure 6d) and AX LN (Figure 6b) was unimpeded. The
ING or AX LNs of these mice did not contain visible mel-
anotic metastases, even though melanotic micrometas-
tases are readily visible on the LN cortex [23] indicating
that the tumors likely block lymph drainage by some other
mechanism.
Figure 5 Coordinate growth of peritumoral IF and ODD lymphatic, vein, and artery triads. a-c): Normal contralateral IF vessel from a
tumor-bearing mouse immunostained with CD31 (a) or 10.1.1 (b) includes small lymphatic, vessel, and artery in triad arrangement.
Immunofluorescent imaging of subcutaneously injected Texas Red Dextran (c) shows Texas Red drainage through the lymphatic vessel, and
circulation through the vein and artery 20 min after injection, demonstrating that all of these vessels are functional. d-f): Peritumoral IF vessel
immunostained with CD31 (d) or 10.1.1 (e) identify enlarged lymphatic, vein, and artery triad. The lymphatic vessel appears to only be partially
10.1.1 antibody-positive, due to collapse of the lymphatic endothelium. Subcutaneously injected Texas Red Dextran is not detected in the
draining IF lymphatic vessel (f), although other lymphatic drainage delivers Dextran to the functional vein and artery. g-i): ODD tumor vessel
immunostained with CD31 (g) or 10.1.1 (h) consists of a triad of large lymphatic, vein, and artery. Texas Red Dextran injection labels the
lymphatic as well as blood vessels, indicating that they are all functional. Scale bar 50 μm.
Ruddell et al. BMC Cancer 2014, 14:354 Page 7 of 11
http://www.biomedcentral.com/1471-2407/14/354Coordinate growth of lymphatic, vein, and artery triads in
an autochthonous tumor model
A murine squamous cell carcinoma model was used to
test whether blood and lymphatic vessel triads are also a
feature of more slowly growing spontaneous tumors.
DMBA mutagenesis followed by TPA promoter treat-
ments in outbred mice [26,29] results in the appearance of
benign papillomas on the treated dorsal skin after 3 to
9 months (Figure 7b), a subset of which sometimes con-
vert to invasive carcinomas (Figure 7c). Tumor growth
and malignant progression is accelerated in mice carrying
a germline deletion in the p19/Arf tumor suppressor gene
[28]. Inspection of the ventral surface of the dorsal skin of
tumor-bearing wild-type or p19Arf+/− mice during nec-
ropsy identified abnormal and enlarged blood vessels
draining papillomas (Figure 7e) and carcinomas (Figure 7f)
relative to normal dorsal skin that featured only a few tiny
blood vessels (Figure 7d). The tumor-draining blood ves-
sels often extended to the draining AX LNs [28], resem-
bling the growth of peritumoral B16-F10 blood vessels
toward the ING or AX LNs (Figure 1a).Vessels draining benign papillomas from 3 mice were
dissected, sectioned and immunostained, to identify tri-
ads including thick-walled arteries and veins (Figure 7g),
as detected by immunostaining for vascular endothelial
marker MECA-32 [40]. Multiple lymphatics were de-
tected by 10.1.1 immunostaining (Figure 7h). These
slowly growing benign tumors thus also induce coordin-
ate growth of large vessel triads, with the arteries par-
ticularly enlarged relative to the veins and lymphatics.
There are no major vessels in the dorsal skin of mice
(Figure 7d), so that the origin of these peritumoral ves-
sels is not obvious.
Immunostaining analysis of the red-colored vessels
surrounding DMBA/TPA-induced carcinomas from 6
mice also identified triads of vein, artery, and lymphatics
by CD31 (Figure 7i) and 10.1.1 (Figure 7j) immunostain-
ing. These vessels were greatly enlarged and abnormal,
resembling the vessels draining B16-F10 melanoma
tumors (Figure 3a). The lymphatic vessel shown in
Figure 7j included 10.1.1 Ab-positive flaps that likely are
valves typical of collecting lymphatic vessels [41,42],
Figure 6 Evans Blue lymphography identifies tumor blockade
of lymph drainage. a). Blue dye injected subcutaneously into the
tail base drains into both ING LNs (black dotted circles). However,
blue dye does not appear in the AX LN on the tumor-draining side,
while it does appear in the AX LN on the normal contralateral side
as expected (white dotted circles surround AX LNs). Dotted black
boxes show regions shown at higher power in b-e. b). normal
contralateral AX LN filled with blue dye. c). Tumor-draining AX LN
fails to take up dye. d). Dye appears in normal contralateral ING LN
and draining SE lymphatic vessel. e). Dye appears in tumor-draining
lNG LN but not in draining SE lymphatic vessel.
Figure 7 Large vessel triads containing artery, vein, and
lymphatics arise in autochthonous tumors. a). The dorsal skin of
a control mouse. b). The dorsal skin of a p19Arf+/− mouse bearing
DMBA/TPA- induced papillomas. c). The dorsal skin of a p19Arf+/−
mouse bearing DMBA/TPA-induced invasive carcinomas. d). Normal
ventral skin is relatively avascular with sparse and very small blood
vessels. e). Ventral skin beneath the papillomas (b) shows highly
abnormal and enlarged red-colored vessels. f). The ventral skin
beneath the carcinomas (c) shows highly abnormal and enlarged
red-colored vessels. g). MECA-32 immunohistochemical staining of a
papilloma-associated vessel from a p19Arf+/− mouse identifies large veins
and thick walled arteries. h). 10.1.1 immunohistochemical staining of
the same papilloma-associated vessel (g) identifies five lymphatic
vessels. i). CD31 immunohistochemical staining of a carcinoma-associated
vessel from a wild-type mouse identifies large lymphatics, vein,
and artery. j). 10.1.1 immunohistochemical staining of the same
carcinoma-associated vessel (i) identifies 2 lymphatic vessels. k). CD31
immunohistochemical staining of a carcinoma-associated vessel from
another wild-type mouse identifies disorganized cluster of enlarged
blood and lymphatic vessels. l). 10.1.1 immunohistochemical staining
of the same carcinoma-associated vessel (k) identifies clustered
enlarged lymphatic vessels. Scale bar 50 μm.
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phatics (data not shown). Other carcinoma-associated
vessels showed more extreme enlargement and dis-
organization, although they maintained clustering of mul-
tiple blood vessels (Figure 7k) and lymphatics (Figure 7l).
These findings identify coordinate growth of peritumoral
lymphatic and blood vessels in autochthonous papillomas
and carcinomas.
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The enlarged red-colored vessels arising over some dis-
tance from spontaneous or implanted tumors include
clustered lymphatics, veins, and arteries, demonstrating
that the triad arrangement typical of large vessels is uti-
lized during tumor-induced angiogenesis and lymphan-
giogenesis. The peritumoral SE and IF vessels likely
grow by enlargement of the pre-existing normal vessel
triads. Blood and lymphatic vessels can both enlarge by
endothelial proliferation, incorporation of bone marrow-
derived cells [43,44], and/or by thinning and dilation
[45]. The “odd” vessels that appear surrounding melano-
mas, papillomas, and carcinomas could similarly be gen-
erated by expansion from very small vessel triads, or
they could potentially arise by recapitulation of their ini-
tial formation in embryos [3,46,47]. The latter possibility
could involve assembly of endothelial progenitors, as oc-
curs in development of the dorsal artery and cardinal
vein [48,49], or sprouting of lymphatic vessels from
small veins [50,51]. Further studies of the generation of
these “odd” vessel triads growing around tumors will be
required to identify the mechanisms guiding this coord-
inate blood and lymphatic vessel growth.
Many of the peritumoral vessels grow toward the re-
gional LNs in the melanoma and squamous cell carcin-
oma models, raising the question of how this expansion
is related to lymph node metastasis. Only the lymphatic
vessel would directly connect the tumor to the draining
LN to deliver tumor cells, so that the enlargement of
functional lymphatic vessels could facilitate LN metasta-
sis. In fact, prostaglandin and VEGF-D-induced enlarge-
ment of collecting lymphatic vessels has recently been
demonstrated to promote metastasis to draining LNs [45].
Other studies have found that VEGF-C and VEGF-D- ex-
pressing tumors induce lymphangiogenesis and increase
metastasis [10-12]. The coordinate growth of large blood
and lymphatic vessel triads thus not only supports tumor
growth and fluid drainage, but also likely promotes
lymphatic metastasis to draining lymph nodes.
The large blood vessels in the vicinity of B16-F10 mela-
nomas were always functional in circulating blood, how-
ever lymphatic vessels were sometimes blocked. Blocked
lymph drainage was readily identified upon necropsy after
Evans Blue subcutaneous injection into the tail base, with
dye usually reaching the ING LN but not the second tier
draining AX LN, and this blockade could be confirmed by
subcutaneous injection of Texas Red Dextran followed by
immunostaining analysis. Our identification of altered
lymphatic drainage is relevant for lymphography mapping
of the sentinel tumor-draining LN in human cancer pa-
tients, for pathology analysis to diagnose whether the
tumor has metastasized [52,53]. The accuracy of sentinel
LN identification has been improved [54,55], however the
difficulties in correctly identifying the tumor-draining LNcould be caused by blocked lymphatic drainage as experi-
mentally demonstrated here.
Recent studies have identified effects of large LN me-
tastases to block tumor lymphatic drainage in mouse
tumor models [56,57]. In our study, mice showing
blocked lymph drainage did not yet contain metastases
in the ING or AX LNs, even though melanotic metasta-
ses consisting of less than 1,000 cells can readily be visu-
alized on the LN cortical surface [23]. Those tumors
demonstrating blocked lymph drainage were not larger
or located closer to the SE or IF vessel triads relative to
tumors with functional lymphatics, so that blocked
drainage is not readily explained by tumor overgrowth.
However, these tumors could potentially compress the
lymphatic vessels to impair lymph drainage. Alterna-
tively, in-transit metastases in tumor-draining lymphatic
vessels have been identified in murine and human mela-
nomas [58,59], which could potentially block lymph
drainage before lymph node metastases are detectible.
Both of the murine tumor models investigated here
exhibited coordinate growth of tumor-draining lymph-
atic and blood vessel triads, suggesting that tumors pro-
duce factors promoting growth of both types of vessels.
Members of the VEGF family of endothelial growth fac-
tors (VEGF-A, −C, −D) show overlapping specificity for
VEGF receptors expressed on lymphatic and blood ves-
sels [16,60], which could potentially drive the concerted
growth of both types of vessels [19,61,62]. Our RT-PCR
analysis of B16-F10 melanoma cells identified abundant
VEGF-A, VEGF-C, and VEGF-D expression at the
mRNA level (data not shown), and B16-F10 melanomas
[63] and DMBA-TPA-induced papillomas [64] produce
high levels of VEGF-A protein. It remains to be deter-
mined whether these VEGFs or other endothelial growth
factors coordinate growth of the blood and lymphatic
vessel triads. Investigation of the mechanisms coordinat-
ing growth of these peritumoral vessel triads could help
to define therapeutic strategies to effectively block both
tumor angiogenesis and lymphangiogenesis.
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